Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy

Figure 1 Patient acquisition flow diagram. PCNSL: Primary central nervous system lymphoma; HD-MTX: High-dose methotrexate; ASCT: Autologous stem cell transplantation; BEAM: Carmustine, etoposide, cytarabine, and melphalan; BEAC: Carmustine, etoposide, cytarabine, and cyclophosphamide; CFS: Cancer Fatigue Scale. R:21 days/month: Lenalidomide for maintenance therapy.

Figure 2 Clinical response and progression-free survival of all patients. o: using a zanubrutinib-based maintenance regimen. *: Using ASCT as a consolidation regimen; →: Ongoing; －: PD; ID: Identification number; PD: Progressive disease; CR: Complete response; PR: Partial response; PFS: Progression-free survival; ASCT: Autologous stem cell transplantation.

Figure 3 Kaplan-Meier curve for overall survival and progression-free survival. A: overall survival; B: progression-free survival. OS: Overall survival; PFS: Progression-free survival.

Figure 4 Gene alterations detected in tumor tissue and cerebrospinal fluid. A: Tumor tissue; B: Cerebrospinal fluid. CSF: Cerebrospinal fluid; P: Patient.

Figure 5 Concordance between baseline primary tumor tissue and cerebrospinal fluid samples for mutation detection. CSF: Cerebrospinal fluid.

Figure 6 Disease monitoring during therapy by evaluating cerebrospinal fluid circulating tumor DNA. A: P8; B: P3. PR: Partial response; SD: Stable disease; P8: Patient 8; P3: Patient 3.